FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

GILMORE JAMES III 		2. Issuer Name and Ticker or Trading Symbol

BARR PHARMACEUTICALS INC [ BRL ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Insider
(Last)          (First)          (Middle)

BARR PHARMACEUTICALS, INC., 400 CHESTNUT RIDGE ROAD 		3. Date of Earliest Transaction (MM/DD/YYYY)

12/16/2008
(Street)

WOODCLIFF LAKE, NJ 07677
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Barr Pharmaceuticals, Inc.   12/16/2008     M    6599   A $48.84   6599   D    
Barr Pharmaceuticals, Inc.   12/16/2008     S    100   D $69.095   6499   D    
Barr Pharmaceuticals, Inc.   12/16/2008     S    200   D $65.105   6299   D    
Barr Pharmaceuticals, Inc.   12/16/2008     S    1600   D $65.11   4699   D    
Barr Pharmaceuticals, Inc.   12/16/2008     S    300   D $65.115   4399   D    
Barr Pharmaceuticals, Inc.   12/16/2008     S    400   D $65.12   3999   D    
Barr Pharmaceuticals, Inc.   12/16/2008     S    100   D $65.135   3899   D    
Barr Pharmaceuticals, Inc.   12/16/2008     S    200   D $65.14   3699   D    
Barr Pharmaceuticals, Inc.   12/16/2008     S    500   D $65.15   3199   D    
Barr Pharmaceuticals, Inc.   12/16/2008     S    500   D $65.155   2699   D    
Barr Pharmaceuticals, Inc.   12/16/2008     S    100   D $65.165   2599   D    
Barr Pharmaceuticals, Inc.   12/16/2008     S    500   D $65.17   2099   D    
Barr Pharmaceuticals, Inc.   12/16/2008     S    500   D $65.18   1599   D    
Barr Pharmaceuticals, Inc.   12/16/2008     S    100   D $65.185   1499   D    
Barr Pharmaceuticals, Inc.   12/16/2008     S    300   D $65.19   1199   D    
Barr Pharmaceuticals, Inc.   12/16/2008     S    100   D $65.21   1099   D    
Barr Pharmaceuticals, Inc.   12/16/2008     S    100   D $65.215   999   D    
Barr Pharmaceuticals, Inc.   12/16/2008     S    300   D $65.24   699   D    
Barr Pharmaceuticals, Inc.   12/16/2008     S    300   D $65.25   399   D    
Barr Pharmaceuticals, Inc.   12/16/2008     S    200   D $65.255   199   D    
Barr Pharmaceuticals, Inc.   12/16/2008     S    99   D $65.26   100   D    
Barr Pharmaceuticals, Inc.   12/16/2008     S    100   D $65.265   0   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Director Stock Plan   $48.84   12/16/2008     M        6599    5/17/2007   11/9/2016   Barr Pharmaceuticals, Inc.   6599   $0.00   13401   D    

Explanation of Responses:

Remarks:
This is part 1 of 3 of a multi-filing

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
GILMORE JAMES III
BARR PHARMACEUTICALS, INC.
400 CHESTNUT RIDGE ROAD
WOODCLIFF LAKE, NJ 07677

Insider

Signatures
S/S William T McKee as Attorney-in-Fact for James Gilmore III 12/18/2008
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Barr (NYSE:BRL)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Barr Charts.
Barr (NYSE:BRL)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Barr Charts.